NEW YORK, August 18, 2016 /PRNewswire/ --
Stock-Callers.com is currently focused on the Medical Appliances and Equipment segment, which includes companies that manufacture medical supplies such as surgical and medical instruments, dental equipment, and surgical appliances. According to IBISWorld, global revenue of this industry is about $350 billion. Let us take a look at today's lineup: Zimmer Biomet Holdings Inc. (NYSE: ZBH), Stryker Corp. (NYSE: SYK), ABIOMED Inc. (NASDAQ: ABMD), and The Spectranetics Corp. (NASDAQ: SPNC). Sign up today and download for free the research reports for the stocks covered today at:
Zimmer Biomet Holdings
On Wednesday, shares in Warsaw, Indiana headquartered Zimmer Biomet Holdings Inc. recorded a trading volume of 1.41 million shares. The stock ended the day at $127.78, which was a slight drop of 0.41%. The Company's shares have gained 2.62% in the last one month, 7.76% over the previous three months, and 25.09% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 3.37% and 16.41%, respectively. Furthermore, shares of Zimmer Biomet Holdings, which together with its subsidiaries, provides musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific, have a Relative Strength Index (RSI) of 51.75.
On August 11th, 2016, research firm SunTrust initiated a 'Buy' rating on the Company's stock, issuing a target price of $155 per share.
On August 15th, 2016, the company announced the acquisition of CD Diagnostics, a fully-integrated, Delaware-based diagnostics company focused on developing immunoassays and biomarker testing to inform treatment decisions that improve patient outcomes. The financial terms of the transaction were not disclosed. ZBH complete research report is just a click away at:
Kalamazoo, Michigan headquartered Stryker Corp.'s stock finished yesterday's session 0.29% lower at $113.15 and with a total volume of 1.10 million shares traded. The Company's shares have gained 3.34% over the previous three months and 22.59% on an YTD basis. The stock is trading above its 200-day moving average by 8.10%. Furthermore, shares of Stryker, which together with its subsidiaries, operates as a medical technology company, have an RSI of 33.83.
On July 27th, 2016, Stryker announced that its Board of Directors has declared a quarterly dividend of $0.38 per share payable on October 31st, 2016 to shareholders of record at the close of business on September 30th, 2016, representing an increase of 10% versus the prior year. The complimentary report on SYK can be downloaded at:
At the closing bell, shares in Danvers, Massachusetts headquartered ABIOMED Inc. saw a slight decline of 0.57%, ending the day at $121.76. The stock recorded a trading volume of 261,279 shares. The Company's shares have advanced 4.43% in the last one month, 28.09% in the previous three months, and 34.87% since the start of this year. The stock is trading 8.27% above its 50-day moving average and 29.17% above its 200-day moving average. Moreover, shares of ABIOMED, which engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart, have an RSI of 63.30.
On July 28th, 2016, Abiomed reported Q1 FY17 revenue of $103.0 million, an increase of 40% compared to revenue of $73.4 million for Q1 FY16. Q1 FY17 GAAP net income was $12.9 million, or $0.29 per diluted share, compared to GAAP net income of $8.9 million, or $0.20 per diluted share, for the prior year period. Sign up for your complimentary report on ABMD at:
Colorado Springs, Colorado headquartered The Spectranetics Corp.'s stock ended the day 0.16% lower at $24.78 and with a total volume of 295,538 shares traded. The Company's shares have gained 21.29% in the last month, 47.76% over the previous three months, and 64.54% on an YTD basis. The stock is trading 19.00% above its 50-day moving average and 51.22% above its 200-day moving average. Additionally, shares of The Spectranetics, which together with its subsidiaries, develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system, have an RSI of 66.93.
On August 09th, 2016, research firm Needham downgraded the Company's stock rating from 'Strong Buy' to 'Buy', issuing a target price of $27 per share.
On August 10th, 2016, Spectranetics announced receipt of CE marking for the AngioSculptX Drug-coated PTCA Scoring Balloon Catheter. AngioSculptX is a first-of-its-kind device, combining the proven AngioSculpt PTCA scoring balloon catheter with a drug coating. It is indicated for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis. As part of the original acquisition of AngioScore, Inc., there is a $5 million milestone payment related to receiving CE mark for AngioSculptX that the company expects to pay in Q3. Download the research report for free on SPNC at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA